title: Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis.
abstract: Chronic myelogenous leukemia (CML) and tuberculosis (TB) are diseases with effective available therapy. Treating patients who are afflicted simultaneously with both of these conditions is challenging due to significant drug interactions and the requirement of strict adherence to the multi-agent treatment regimen. Here, we report a case of peritoneal tuberculosis which was successfully treated with a non-rifampin based regimen in tandem with ongoing administration of a tyrosine kinase inhibitor, dasatinib, for CML. We discuss treatment challenges and the strategy on how to circumvent them. As prevalence of CML increases worldwide, patients with concomitant CML and TB will be seen more often by physicians in all continents, and development of guidelines on simultaneous management of these conditions is imperative.
authors.affiliation: Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore. aemadi@umm.edu.
authors.forename: Vishal
authors.initials: V
authors.lastname: Bhatnagar
authors.affiliation: Prince Georges County Health Department, Cheverly.
authors.forename: Akintoye
authors.initials: A
authors.lastname: Adelakun
authors.affiliation: Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore.
authors.forename: Trisha
authors.initials: T
authors.lastname: Kendall
authors.affiliation: Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore.
authors.forename: Noa
authors.initials: N
authors.lastname: Holtzman
authors.affiliation: Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore.
authors.forename: Maham
authors.initials: M
authors.lastname: Farshidpour
authors.affiliation: Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore.
authors.forename: Brandi
authors.initials: B
authors.lastname: Stevenson
authors.affiliation: Department of Pathology, School of Medicine, University of Maryland, Baltimore.
authors.forename: Qing
authors.initials: Q
authors.lastname: Chen
authors.affiliation: Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore.
authors.forename: Ashkan
authors.initials: A
authors.lastname: Emadi
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D000069439:Dasatinib; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D000077266:Moxifloxacin; D014395:Peritonitis, Tuberculous / Q000150:complications / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011718:Pyrazinamide / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D000995:Antitubercular Agents; D024841:Fluoroquinolones; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011718:Pyrazinamide; D004977:Ethambutol; D000069439:Dasatinib; D000077266:Moxifloxacin; D007538:Isoniazid